BioVie shares Phase 2 bezisterim data for Long COVID treatment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. CRWD
2. REGN
3. LITE
4. AAPL
5. ABBV
6. MRVL
7. CL
8. PLTR
9. LYB
10. TFII

Go back to BioVie shares Phase 2 bezisterim data for Long COVID treatment

BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting

October 19, 2026 8:00 AM EDT

CARSON CITY, Nev., Oct. 19, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (BioVie or the Company), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the presentation of results from the Phase 2 ADDRESS-LC study (NCT06847191) evaluating bezisterim (NE3107) in patients with Long COVID at the 151st Annual Meeting of the American Neurological Association (ANA), held October 1720, 2026, in San Diego, California. The studys abstract was published in Annals of Neurology (Vol. 100, pp. S4S375,... More